Search Within

Malin Lisa Hultcrantz

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (73)
  2. Journal Article (20)
  3. Research Letter (4)
  4. Correspondence (2)
Groups
  1. Biostatistics Service (99)
  2. Center for Hematologic Malignancies (99)
  3. Department of Medicine (99)
  4. Epidemiology and Biostatistics (99)
  5. Hematologic Malignancies, Division of (99)
  6. Myeloma (99)

More Groups

People
  1. Alexander Lesokhin (90)
  2. Sham Mailankody (89)
  3. Hani Hassoun (87)
  4. Neha Korde (86)
  5. Urvi Shah (84)
  6. Carlyn Rose Tan (78)

More People

Years
  1. 2025 (2)
  2. 2024 (15)
  3. 2023 (24)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (11)

More Years

Publications
  1. Blood (41)
  2. Clinical Lymphoma, Myeloma and Leukemia (24)
  3. Journal of Clinical Oncology (8)
  4. Blood Cancer Journal (5)
  5. American Journal of Hematology (2)
  6. Blood Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. Elsevier Inc. (26)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (7)
  5. American Association for Cancer Research (4)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (99)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies
    Journal Article

    Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
    Journal Article

    Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Journal Article

    Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
    Journal Article

    Oben, B.; Froyen, G.; Maclachlan, K. H.; Leongamornlert, D.; Abascal, F.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Geerdens, E.; Diamond, B. T.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers
    Journal Article

    Hultcrantz, M.; Richter, J.; Rosenbaum, C. A.; Patel, D.; Smith, E. L.; Korde, N.; Lu, S. X.; Mailankody, S.; Shah, U. A.; Lesokhin, A. M.; more...
    Blood Cancer Discovery (2020)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save